Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions.
Immune haemolytic anaemia (IHA) is a recognised complication after allogeneic stem cell transplantation (SCT) and occurs more frequently if marrow cells have been subjected to T cell depletion (TCD). Among 58 consecutive patients who underwent TCD-allogeneic SCT from volunteer unrelated donors for the treatment of CML at the Hammersmith Hospital during a 3-year period (1 March 1996 to 28 February 1999) we identified nine cases of IHA. All patients had a strongly positive direct and indirect antiglobulin test and in eight patients the serological findings were typical of warm-type haemolysis often with antibody specificities within the Rh system. All nine cases had clinically significant haemolysis and were treated initially with prednisolone and immunoglobulin. The onset of IHA coincided with the occurrence of leukaemic relapse in six cases, and the presence of host haemopoiesis confirmed by lineage-specific chimerism in all four cases studied. Five patients received donor lymphocyte infusions (DLI); in three molecular remission and the restoration of full donor chimerism coincided with resolution of haemolysis. We conclude that in the context of leukaemic relapse, DLI is an effective therapy for IHA following allografts involving TCD.
Cwynarski
K
K
Department of Haematology, Hammersmith Hospital, ICSM, London, UK.
Goulding
R
R
Pocock
C
C
Dazzi
F
F
Craddock
C
C
Kaeda
J
J
Olavarria
E
E
Kanfer
E
E
Apperley
J
J
Lawler
M
M
Goldman
J M
JM
D000293:Adolescent; D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000379:methods; D005260:Female; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000628:therapy; D008212:Lymphocyte Depletion / Q000009:adverse effects*; D017710:Lymphocyte Transfusion; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D018183:Transplantation Chimera; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000276:immunology / Q000379:methods; D016896:Treatment Outcome
D007518:Isoantibodies